Last 7 days
5.3%
Last 30 days
-12.8%
Last 90 days
-27.8%
Trailing 12 Months
1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -9.9% | 19,263 | 21,390 | 22,995 | 22,600 | 18,471 |
S&GA Expenses | 18.2% | 1,132 | 958 | 848 | 758 | 567 |
R&D Expenses | 20.6% | 3,295 | 2,732 | 2,433 | 2,144 | 1,991 |
EBITDA | -37.7% | 9,948 | 15,968 | 16,564 | 13,531 | - |
EBITDA Margin | -25.6% | 0.52* | 0.69* | 0.73* | 0.73* | - |
Earnings Before Taxes | -28.2% | 9,575 | 13,330 | 15,665 | 16,254 | 13,285 |
EBT Margin | -20.2% | 0.50* | 0.62* | 0.68* | 0.72* | - |
Interest Expenses | 78.6% | 25.00 | 14.00 | - | - | - |
Net Income | -28.9% | 8,362 | 11,765 | 14,055 | 14,638 | 12,202 |
Net Income Margin | -21.1% | 0.43* | 0.55* | 0.61* | 0.65* | - |
Free Cahsflow | -26.1% | 4,581 | 6,201 | 9,215 | 13,031 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -0.8% | 25,858 | 26,056 | 26,043 | 27,609 | 24,669 |
Current Assets | -6.1% | 13,431 | 14,297 | 13,563 | 16,350 | 16,071 |
Cash Equivalents | 5.9% | 3,205 | 3,027 | 2,873 | 5,048 | 6,848 |
Inventory | -54.3% | 949 | 2,077 | 1,921 | 1,942 | 1,441 |
Liabilities | -16.5% | 6,735 | 8,064 | 8,058 | 10,534 | 10,524 |
Current Liabilities | -27.7% | 4,923 | 6,807 | 6,812 | 9,238 | 9,128 |
Shareholder's Equity | 6.3% | 19,123 | 17,992 | 17,985 | 17,075 | 14,145 |
Retained Earnings | 8.7% | 18,320 | 16,855 | 15,812 | 13,615 | 9,958 |
Additional Paid-In Capital | -21.2% | 1,173 | 1,488 | 2,413 | 3,644 | 4,211 |
Shares Outstanding | -0.5% | 385 | 387 | 392 | 400 | 403 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -24.9% | 4,981 | 6,629 | 9,653 | 13,412 | 13,620 |
Share Based Compensation | 12.4% | 226 | 201 | 171 | 156 | 142 |
Cashflow From Investing | 1.7% | -5,176 | -5,266 | -9,538 | -12,264 | -8,523 |
Cashflow From Financing | 11.2% | -3,448 | -3,883 | -2,844 | -1,541 | -873 |
Buy Backs | -12.0% | 3,329 | 3,784 | 2,778 | 1,480 | 857 |
99.1%
81.4%
49.1%
Y-axis is the maximum loss one would have experienced if Moderna was unfortunately bought at previous high price.
91.5%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 4.98 | 674,929 | 1,810,930 | 0.05% |
2023-03-13 | Claro Advisors LLC | reduced | -10.03 | 44,165 | 380,165 | 0.12% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -1.09 | 2,690,230,000 | 8,044,600,000 | 8.38% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 60.78 | 49,677,000 | 84,122,000 | 0.09% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -8.35 | 334,312 | 1,185,310 | 0.02% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | new | - | 265,658 | 265,658 | 0.04% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 182 | 16,322,000 | 21,280,000 | 0.11% |
2023-03-03 | TIAA, FSB | added | 55.63 | 551,758 | 955,758 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 176,925 | 176,925 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | reduced | -8.13 | 5,297 | 20,297 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 7.10% | 27,282,173 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.8% | 26,115,224 | SC 13G/A | |
Jan 19, 2023 | baillie gifford & co | 11.66% | 44,786,746 | SC 13G/A | |
Feb 14, 2022 | bancel stephane | 7.64% | 31,538,184 | SC 13G/A | |
Feb 14, 2022 | flagship ventures fund iv general partner llc | 2.8% | 11,460,435 | SC 13G/A | |
Feb 04, 2022 | blackrock inc. | 6.8% | 27,661,473 | SC 13G | |
Jan 26, 2022 | baillie gifford & co | 11.29% | 45,772,079 | SC 13G/A | |
Jul 12, 2021 | blackrock inc. | 4.8% | 19,390,725 | SC 13G/A | |
Mar 01, 2021 | baillie gifford & co | 11.18% | 44,691,386 | SC 13G/A | |
Feb 16, 2021 | flagship ventures fund iv general partner llc | 2.9% | 11,460,435 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 956.74 530.35% | 1239.83 716.86% | 2702.82 1680.75% | 4476.90 2849.60% | 7528.63 4860.23% |
Current Inflation | 878.54 478.82% | 1122.30 639.43% | 2389.70 1474.45% | 3898.91 2468.79% | 6493.86 4178.47% |
Very High Inflation | 781.19 414.69% | 978.77 544.86% | 2017.09 1228.96% | 3222.56 2023.18% | 5294.41 3388.21% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | DEF 14A | DEF 14A | |
Mar 15, 2023 | DEFA14A | DEFA14A | |
Mar 10, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-09 | Bancel Stephane | acquired | 39,600 | 0.99 | 40,000 | chief executive officer |
2023-03-09 | Bancel Stephane | sold | -5,567,860 | 139 | -40,000 | chief executive officer |
2023-03-08 | Klinger Shannon Thyme | sold | -79,387 | 141 | -561 | chief legal officer |
2023-03-08 | Bancel Stephane | acquired | 39,600 | 0.99 | 40,000 | chief executive officer |
2023-03-08 | Bancel Stephane | sold | -5,655,310 | 141 | -40,000 | chief executive officer |
2023-03-07 | Klinger Shannon Thyme | acquired | - | - | 1,138 | chief legal officer |
2023-03-02 | Bancel Stephane | acquired | 39,600 | 0.99 | 40,000 | chief executive officer |
2023-03-02 | Hoge Stephen | sold | -160,583 | 136 | -1,177 | president |
2023-03-02 | Bancel Stephane | sold | -5,500,040 | 137 | -40,000 | chief executive officer |
2023-03-02 | Klinger Shannon Thyme | sold | -62,623 | 136 | -459 | chief legal officer |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 19,263 | $ 18,471 | $ 803 |
Operating expenses: | |||
Cost of sales | 5,416 | 2,617 | 8 |
Research and development | 3,295 | 1,991 | 1,370 |
Selling, general and administrative | 1,132 | 567 | 188 |
Total operating expenses | 9,843 | 5,175 | 1,566 |
Income (loss) from operations | 9,420 | 13,296 | (763) |
Interest income | 200 | 18 | 25 |
Other expense, net | (45) | (29) | (6) |
Income (loss) before income taxes | 9,575 | 13,285 | (744) |
Provision for income taxes | 1,213 | 1,083 | 3 |
Net income (loss) | $ 8,362 | $ 12,202 | $ (747) |
Earnings (loss) per share: | |||
Basic (in usd per share) | $ 21.26 | $ 30.31 | $ (1.96) |
Diluted (in usd per share) | $ 20.12 | $ 28.29 | $ (1.96) |
Weighted average common shares used in calculation of earnings (loss) per share: | |||
Basic (in shares) | 394 | 403 | 381 |
Diluted (in shares) | 416 | 431 | 381 |
Product sales | |||
Revenue: | |||
Total revenue | $ 18,435 | $ 17,675 | $ 200 |
Grant revenue | |||
Revenue: | |||
Total revenue | 388 | 735 | 529 |
Collaboration revenue | |||
Revenue: | |||
Total revenue | $ 440 | $ 61 | $ 74 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,205 | $ 6,848 |
Investments | 6,697 | 3,879 |
Accounts receivable | 1,385 | 3,175 |
Inventory | 949 | 1,441 |
Prepaid expenses and other current assets | 1,195 | 728 |
Total current assets | 13,431 | 16,071 |
Investments, non-current | 8,318 | 6,843 |
Property, plant and equipment, net | 2,018 | 1,241 |
Right-of-use assets, operating leases | 121 | 142 |
Deferred tax assets | 982 | 326 |
Other non-current assets | 988 | 46 |
Total assets | 25,858 | 24,669 |
Current liabilities: | ||
Accounts payable | 487 | 302 |
Accrued liabilities | 2,101 | 1,472 |
Deferred revenue | 2,038 | 6,253 |
Income taxes payable | 48 | 876 |
Other current liabilities | 249 | 225 |
Total current liabilities | 4,923 | 9,128 |
Deferred revenue, non-current | 673 | 615 |
Operating lease liabilities, non-current | 92 | 106 |
Financing lease liabilities, non-current | 912 | 599 |
Other non-current liabilities | 135 | 76 |
Total liabilities | 6,735 | 10,524 |
Commitments and contingencies (Note 12) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2022 and 2021; no shares issued or outstanding at December 31, 2022 and 2021 | 0 | 0 |
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2022 and 2021; 385 and 403 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 0 | 0 |
Additional paid-in capital | 1,173 | 4,211 |
Accumulated other comprehensive loss | (370) | (24) |
Retained earnings | 18,320 | 9,958 |
Total stockholders’ equity | 19,123 | 14,145 |
Total liabilities and stockholders’ equity | $ 25,858 | $ 24,669 |